New Board Member Brings Life Sciences Tools Experience to the Leader in
Cellular Bioenergetic Profiling
N. BILLERICA, Mass., Aug. 10 /PRNewswire/ -- Seahorse Bioscience, the leading provider of tools for real-time measurement of cellular bioenergetics in microplates, announced today that former Molecular Devices executive Joseph Keegan has been appointed to the company's Board of Directors. In this position, Keegan will apply his successful business experience in the life sciences industry to accelerate the growth of Seahorse Bioscience's novel technology for profiling cell metabolism.
"As the company moves into its next phase of growth, it will require a strong understanding of this market," said Jay Teich, Seahorse Bioscience's CEO. "Joe's tremendous success in building Molecular Devices, combined with his extensive labware experience makes him an ideal addition to our Board."
Keegan brings more than 25 years of experience managing life science tools businesses. As CEO of Molecular Devices, he developed a strategy combining internal growth with acquisitions to build the dominant supplier of detection solutions for drug discovery, clinical and research applications. Keegan joined MDC from Becton Dickinson and Company where he served as President of Worldwide Tissue Culture. Prior to Becton Dickinson, Keegan was Vice President of Microscopy and Scientific Instruments Division of Leica, Inc.
"Seahorse has developed a 'stethoscope for living cells.' The ability to measure cell metabolism in a truly non-invasive way has very broad applications," said Keegan. "Drawing on my experience with both instrument and labware businesses, I look forward to helping Seahorse grow a successful business in a field that I understand very well."
About Seahorse Bioscience
Seahorse Bioscience is changing cancer, obesity and diabetes drug
discovery programs the world over. Seahorse headquarters are located in
|SOURCE Seahorse Bioscience|
Copyright©2007 PR Newswire.
All rights reserved